OCT 13, 2016 1:32 PM PDT

Limiting Immune Damage from Type 1 Diabetes

WRITTEN BY: Kara Marker
Over seven percent of individuals in the UK with type 1 diabetes are children, and the autoimmune diseases grows more common every year. Using a recombinant version of a chemical naturally produced already in the body, researchers from Cambridge are on the brink of a new treatment for type 1 diabetes that could reduce or even completely eliminate the need for regular insulin injections.
Image credit: Children's Hospital Los Angeles
When the body’s immune cells mistaken the insulin-producing cells of the pancreas, called beta cells, blood glucose levels begin to rise. This what defines type 1 diabetes, and this is what requires individuals with this disease to administer regular insulin shots to regulate blood glucose levels.

A study from the University of Cambridge JDRF/Wellcome Trust Diabetes Inflammation Laboratory at the Cambridge Institute of Medical Research led to the proposition of a new drug to regulate the type 1 diabetes autoimmune response: aldesleukin, a recombinant version of interleukin-2 (IL), a cytokine that wears many hats in the immune system. Aldesleukin is currently approved by the Food and Drug Administration (FDA) to treat melanoma and renal cell carcinoma in high doses.

“The current treatment [for type 1 diabetes] - multiple daily injections of insulin - are at best inconvenient, at worst painful, particularly for children," says Dr Frank Waldron-Lynch, who led the study. "Our goal is to develop a treatment that could see the end to the need for these life-long, daily injections by curtailing the early damage caused by the patient's own immune system.”

Waldron-Lynch and his team conducted their study to measure the ability of aldesleukin to regulate the immune response, using lower doses than the drug is currently used for to treat cancer. In the case of type 1 diabetes, aldesleukin works by enhancing the activity of regulatory T cells, which can limit the immune responses in autoimmune reactions. 

The results from extensive immune monitoring in 40 patients showed that the doses increased the level of regulatory T cells by 10-20 percent, the minimum needed to prevent an immune attack on insulin-producing cells and the maximum level to leave the effector immune cell activity intact in order to keep the rest of the body protected from infection.

Additionally, the results suggest that the drug shouldn’t be administered on a daily basis, so regulatory T cells won’t lose any sensitivity to aldesleukin.

"Our work is at an early stage, but it uses a drug that occurs naturally within the body to restore the immune system to health in these patients,” Waldron-Lynch said. “Whereas previous approaches have focused on suppressing the immune system, we are looking to fine-tune it.” 

In the future, Waldron-Lynch and the team plan on focusing the new aldesleukin-based treatment on people newly-diagnosed with type 1 diabetes who are still able to produce some insulin from beta cells. The study was recently published in PLOS Medicine.
 


Sources: University of Cambridge, American Diabetes Association, National Cancer Institute, Cytokine
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 25, 2021
Immunology
Battling Bacterial Pneumonia, No Antibiotics Required
NOV 25, 2021
Battling Bacterial Pneumonia, No Antibiotics Required
Instead of flooding the body with antibiotics, what if we could program cells to fight off pathogens more effectively? T ...
NOV 30, 2021
Immunology
The Body Makes Its Own Anti-inflammatory 'Cannabis' After a Workout
NOV 30, 2021
The Body Makes Its Own Anti-inflammatory 'Cannabis' After a Workout
Feeling great after hitting the gym? That’s because of the flood of endorphins released into the body after a bout ...
DEC 14, 2021
Immunology
Eye Immunity Redefined: Immune Cells Do Enter the Lens After All
DEC 14, 2021
Eye Immunity Redefined: Immune Cells Do Enter the Lens After All
The eyes may be the windows to the soul, but they are also vulnerable access points for environmental pathogens. What&rs ...
JAN 06, 2022
Immunology
Worryingly High Levels of Free Radicals in COVID Patients
JAN 06, 2022
Worryingly High Levels of Free Radicals in COVID Patients
  COVID-19 infections trigger widespread oxidative damage, says new research by scientists from the Baylor College ...
JAN 06, 2022
Immunology
Gene for Smelling Helps Cancer Cells Move to the Brain
JAN 06, 2022
Gene for Smelling Helps Cancer Cells Move to the Brain
From tasting a delicious meal to picking up pheromones, olfaction (or the sense of smell) involves a network of complex ...
JAN 06, 2022
Health & Medicine
New Hope for Hair Regrowth in Alopecia Areata
JAN 06, 2022
New Hope for Hair Regrowth in Alopecia Areata
Two recently completed phase 3 clinical trials showed the drug baricitinib leads to hair growth for alopecia areata pati ...
Loading Comments...